Do I need a prescription for Ranolazine 375mg modified-release tablets?

Ranolazine 375mg modified-release tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ranolazine 375mg modified-release tablets?

Ranolazine 375mg modified-release tablets is the generic name. It is available under brand names including: Anzipro 375mg modified-release tablets, Ranexa 375mg modified-release tablets, Ranexa 375mg modified-release tablets, Ranexa 375mg modified-release tablets, Ranexa 375mg modified-release tablets and 10 more. (Source: NHS dm+d — Actual Medicinal Products)

Ranolazine 375mg modified-release tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

375mg

Oral

Nitrates, calcium-channel blockers, and other antianginal drugs

Active ingredients:

Ranolazine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.06.03

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C01EB18

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ranolazine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ranolazine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ranolazine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ranolazine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

15 branded products available

15 productsShow details

15 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ranolazine on the MHRA register

Ranexa 375mg modified-release tablets

A. Menarini Farmaceutica Internazionale SRL

Ranexa 375mg modified-release tablets

CST Pharma Ltd

Ranogelan 375mg prolonged-release tablets

G.L. Pharma UK Ltd

Ranolazine 375mg modified-release tablets

Teva UK Ltd

Ranolazine 375mg modified-release tablets

Krka UK Ltd

Ranolazine 375mg modified-release tablets

Celix Pharma Ltd

Ranolazine 375mg modified-release tablets

A A H Pharmaceuticals Ltd

Ranolazine 375mg modified-release tablets

Alliance Healthcare (Distribution) Ltd

Ranolazine 375mg modified-release tablets

Dr Reddy's Laboratories (UK) Ltd

Ranolazine 375mg modified-release tablets

Zentiva Pharma UK Ltd

Ranolazine 375mg modified-release tablets

Aspire Pharma Ltd

Anzipro 375mg modified-release tablets

Ridge Pharma Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£5.78indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

1.5 gram

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Acoramidis 356mg tablets

Tablet

356mg

Same therapeutic group

Mavacamten 10mg capsules

Capsule

10mg

Same therapeutic group

Mavacamten 15mg capsules

Capsule

15mg

Same therapeutic group

Adenosine 6mg/2ml solution for injection ampoules

Injection

6mg/2ml

Same therapeutic group

Mavacamten 2.5mg capsules

Capsule

2.5mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Ranolazine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Stable angina (QS21)

QS21

Quality standard

Updated Feb 2017

Stable angina: management (CG126)

CG126

Clinical guideline

Updated Aug 2016

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ranolazine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

15000811000001106

dm+d ID

15000811000001106

VTM (Virtual Therapeutic Moiety)

777399003

VMP (Virtual Medicinal Product)

15000811000001106

BNF code

02060300

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C01EB18

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

7 hours

Mechanism

Myocardial ischemia exerts effects on adenosine triphosphate flux, leading to a…

Food interactions

2 warnings

Human targets

6 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

2-6 hours

The time to reach peak serum concentration is quite variable but has been observed to be in the range of 2-6 hours, with steady-state within 3 days.
[A174898]…

Half-life

7 hours

The apparent terminal half-life of ranolazine is 7 hours.
[A175030][L3580]

Protein binding

62%

Approximately 62% of the administered dose of ranolazine is bound to plasma proteins.
[A174946][L3580]…

Volume of distribution

53.2 L

The mean apparent volume of distribution of ranolazine is reported to be 53.2…

Metabolism

Ranolazine is rapidly heavily metabolized in the liver an gastrointestinal tract through the activity of the CYP3A4 enzyme with minor contributions from CYP2D6.
[A174898][A174913][L3580]…

Elimination

From the administered dose, about 3/4 of the dose is excreted renally, while 1/4 of the dose is excreted in the feces.…

Clearance

45 L/h

The reported clearance rate of orally administered ranolazine is of 45 L/h when administered at a dose of 500 mg twice daily.
[A38645]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]

Properties:

solid

Avg. mass: 427.54 Da

View FDA drug label

DrugBank indication

Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
[L3580]

Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence.
[A174940]
Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
[A174898][L3580]

Also known as(174)

Ranolazina

Ranolazine

3.4.21.7

NAC1

SCN1

Sodium channel protein brain I subunit alpha

Sodium channel protein type I subunit alpha

Voltage-gated sodium channel subunit alpha Nav1.1

Dosage forms(20)

Granule (Oral) — 1000 mg/1

Granule (Oral) — 500 mg/1

Tablet, extended release (Oral) — 1000 mg

Tablet (Oral) — 500.000 mg

Tablet, film coated, extended release (Oral) — 1000 mg/1

Tablet, film coated, extended release (Oral) — 500 mg/1

Tablet, extended release (Oral) — 375 mg

Tablet, extended release (Oral) — 500 mg

Molecular properties(19)

Drug interactions(1556)

Known interactions with other medications. Always consult a healthcare professional.

Ivabradine

Moderate

DB09083

Ivabradine may increase the QTc-prolonging activities of Ranolazine.

Check this interaction

Bosutinib

Unknown severity

DB06616

The serum concentration of Bosutinib can be increased when it is combined with Ranolazine.

Check this interaction

Brentuximab vedotin

Unknown severity

DB08870

The serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine.

Check this interaction

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Ethinylestradiol

Moderate

DB00977

Ethinylestradiol may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Glyburide

Moderate

DB01016

Glyburide may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Ranolazine which could result in a higher serum level.

Check this interaction

Colchicine

Unknown severity

DB01394

The serum concentration of Colchicine can be increased when it is combined with Ranolazine.

Check this interaction

Edoxaban

Unknown severity

DB09075

The serum concentration of Edoxaban can be increased when it is combined with Ranolazine.

Check this interaction

Ledipasvir

Unknown severity

DB09027

The serum concentration of Ledipasvir can be increased when it is combined with Ranolazine.

Check this interaction

Lomitapide

Moderate

DB08827

The metabolism of Lomitapide can be decreased when combined with Ranolazine.

Check this interaction

Naloxegol

Unknown severity

DB09049

The serum concentration of Naloxegol can be increased when it is combined with Ranolazine.

Check this interaction

Pazopanib

Unknown severity

DB06589

The serum concentration of Pazopanib can be increased when it is combined with Ranolazine.

Check this interaction

Prucalopride

Unknown severity

DB06480

The serum concentration of Prucalopride can be increased when it is combined with Ranolazine.

Check this interaction

Loxapine

Unknown severity

DB00408

The serum concentration of Ranolazine can be increased when it is combined with Loxapine.

Check this interaction

Zonisamide

Unknown severity

DB00909

The serum concentration of Ranolazine can be increased when it is combined with Zonisamide.

Check this interaction

Carvedilol

Unknown severity

DB01136

The serum concentration of Ranolazine can be increased when it is combined with Carvedilol.

Check this interaction

Propafenone

Unknown severity

DB01182

The serum concentration of Ranolazine can be increased when it is combined with Propafenone.

Check this interaction

Lapatinib

Unknown severity

DB01259

The serum concentration of Ranolazine can be increased when it is combined with Lapatinib.

Check this interaction

Mibefradil

Unknown severity

DB01388

The serum concentration of Ranolazine can be increased when it is combined with Mibefradil.

Check this interaction

Biricodar

Unknown severity

DB04851

The serum concentration of Ranolazine can be increased when it is combined with Biricodar.

Check this interaction

Elacridar

Unknown severity

DB04881

The serum concentration of Ranolazine can be increased when it is combined with Elacridar.

Check this interaction

Flibanserin

Unknown severity

DB04908

The serum concentration of Ranolazine can be increased when it is combined with Flibanserin.

Check this interaction

Vandetanib

Unknown severity

DB05294

The serum concentration of Ranolazine can be increased when it is combined with Vandetanib.

Check this interaction

Zosuquidar

Unknown severity

DB06191

The serum concentration of Ranolazine can be increased when it is combined with Zosuquidar.

Check this interaction

Tariquidar

Unknown severity

DB06240

The serum concentration of Ranolazine can be increased when it is combined with Tariquidar.

Check this interaction

Brefeldin A

Unknown severity

DB07348

The serum concentration of Ranolazine can be increased when it is combined with Brefeldin A.

Check this interaction

Ivacaftor

Unknown severity

DB08820

The serum concentration of Ranolazine can be increased when it is combined with Ivacaftor.

Check this interaction

Vorapaxar

Unknown severity

DB09030

The serum concentration of Ranolazine can be increased when it is combined with Vorapaxar.

Check this interaction

Suvorexant

Unknown severity

DB09034

The serum concentration of Ranolazine can be increased when it is combined with Suvorexant.

Check this interaction

Daclatasvir

Unknown severity

DB09102

The serum concentration of Ranolazine can be increased when it is combined with Daclatasvir.

Check this interaction

Niguldipine

Unknown severity

DB09239

The serum concentration of Ranolazine can be increased when it is combined with Niguldipine.

Check this interaction

Rolapitant

Unknown severity

DB09291

The serum concentration of Ranolazine can be increased when it is combined with Rolapitant.

Check this interaction

Neratinib

Unknown severity

DB11828

The serum concentration of Ranolazine can be increased when it is combined with Neratinib.

Check this interaction

Sarecycline

Unknown severity

DB12035

The serum concentration of Ranolazine can be increased when it is combined with Sarecycline.

Check this interaction

Laniquidar

Unknown severity

DB12799

The serum concentration of Ranolazine can be increased when it is combined with Laniquidar.

Check this interaction

Dexniguldipine

Unknown severity

DB14068

The serum concentration of Ranolazine can be increased when it is combined with Dexniguldipine.

Check this interaction

ONT-093

Unknown severity

DB14069

The serum concentration of Ranolazine can be increased when it is combined with ONT-093.

Check this interaction

Istradefylline

Unknown severity

DB11757

The serum concentration of Ranolazine can be increased when it is combined with Istradefylline.

Check this interaction

Erythromycin

Unknown severity

DB00199

The serum concentration of Ranolazine can be increased when it is combined with Erythromycin.

Check this interaction

Reserpine

Unknown severity

DB00206

The serum concentration of Ranolazine can be increased when it is combined with Reserpine.

Check this interaction

Sorafenib

Unknown severity

DB00398

The serum concentration of Ranolazine can be increased when it is combined with Sorafenib.

Check this interaction

Verapamil

Unknown severity

DB00661

The serum concentration of Ranolazine can be increased when it is combined with Verapamil.

Check this interaction

Tacrolimus

Unknown severity

DB00864

The serum concentration of Ranolazine can be increased when it is combined with Tacrolimus.

Check this interaction

Carfilzomib

Unknown severity

DB08889

The serum concentration of Ranolazine can be increased when it is combined with Carfilzomib.

Check this interaction

Entrectinib

Unknown severity

DB11986

The serum concentration of Ranolazine can be increased when it is combined with Entrectinib.

Check this interaction

Erdafitinib

Unknown severity

DB12147

The serum concentration of Ranolazine can be increased when it is combined with Erdafitinib.

Check this interaction

Regorafenib

Unknown severity

DB08896

The serum concentration of Ranolazine can be increased when it is combined with Regorafenib.

Check this interaction

Showing 50 of 1556 interactions

Food & lifestyle interactions

Avoid Grapefruit

Avoid grapefruit products.

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

The reported LD50 of oral ranolazine in the rat is 980 mg/kg.MSDS High oral doses of ranolazine have led to dizziness, nausea, and vomiting. These effects have been shown to be dose related. High intravenous doses can cause diplopia, confusion, paresthesia, in addition to syncope.

In
the case of an overdose, provide supportive therapy accompanied by continuous ECG monitoring for QT interval prolongation.
[L3580]

How it works

Mechanism of action

Myocardial ischemia exerts effects on adenosine triphosphate flux, leading to a decrease in the energy available for contraction and relaxation of the heart muscle. Electrolyte balance of sodium and potassium is necessary for maintaining normal cardiac contraction and relaxation. Disruption of adequate sodium and potassium electrolyte balance leads to excessively high concentrations of sodium and calcium, which likely interferes with oxygen supply to the heart muscle. This imbalance eventually leads to angina symptoms of chest pain or pressure, nausea, and dizziness, among others.[A189234][L10965]

The mechanism of action for ranolazine is not fully understood. At therapeutic concentrations, it can inhibit the cardiac late sodium
205 current (INa), which may affect the electrolyte balance in the myocardium, relieving angina symptoms. The clinical significance this inhibition in the treatment of angina symptoms is not yet confirmed.[L3580]

Ranolazine inhibits sodium and potassium ion channel currents.[A174898] It has been shown to exert weak activity on L-type calcium channels making it a weak direct vasodilator and exerts minimal direct effects on atrioventricular nodal conduction.[A174913] Some additional mechanisms have been elucidated. Ranolazine exerts antagonistic activity towards the alpha 1 and beta 1 adrenergic receptors and inhibition of fatty acid oxidation.[A174898][A189252]

Pharmacodynamics

Ranolazine exerts both antianginal and ischemic effects independent from lowering heart rate or blood pressure.[A189228][L3580] It blocks IKr, the rapid portion of the delayed rectifier potassium current, and prolongs the QTc interval in a dose-dependent fashion. The Ikr is important for cardiac repolarization.[L3580] Ranolazine exerts its therapeutic effects without negative chronotropic, dromotropic, or inotropic actions neither at rest, nor during exercise.[A174898]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The time to reach peak serum concentration is quite variable but has been observed to be in the range of 2-6 hours, with steady-state within 3 days.
[A174898]
The FDA indicates a Tmax of 3-5 hours.
[L3580]
The average steady-state Cmax is about 2600 ng/mL. Absorption of ranolazine is not significantly affected by food consumption.
[A174940]
The bioavailability of ranolazine taken in the tablet form compared to that from a solution of ranolazine is about 76%.
[L3580]

Half-life

The apparent terminal half-life of ranolazine is 7 hours.
[A175030][L3580]

Protein binding

Approximately 62% of the administered dose of ranolazine is bound to plasma proteins.
[A174946][L3580]
Ranolazine appears to have a higher binding affinity for alpha-1 acid glycoprotein.
[A175030][L5473]

Volume of distribution

The mean apparent volume of distribution of ranolazine is reported to be 53.2 L[L5473] and the average steady-state volume of distribution is estimated to range from 85 to 180 L.
[A38645]

Metabolism

Ranolazine is rapidly heavily metabolized in the liver an gastrointestinal tract through the activity of the CYP3A4 enzyme with minor contributions from CYP2D6.
[A174898][A174913][L3580]

More than 40 ranolazine metabolites have been found in plasma and more than 100 metabolites have been identified in the urine.
[A174946]

Ranolazine and some of its metabolites are known to weakly inhibit CYP3A4. However, the activity of the metabolites of ranolazine has not been fully elucidated.
[L5473]

Route of elimination

From the administered dose, about 3/4 of the dose is excreted renally, while 1/4 of the dose is excreted in the feces. An estimated 5% of an ingested dose is excreted as unchanged drug.
[A174898][L3580]

Clearance

The reported clearance rate of orally administered ranolazine is of 45 L/h when administered at a dose of 500 mg twice daily.
[A38645]
The clearance rate of ranolazine is dose-dependent and renal impairment can increase ranolazine serum concentration by 40-50%.
[A174946]

Drug targets(6)

Proteins and enzymes this drug interacts with in the body

Plasminogen

BE0000211

PLG

modulator

Specific functionapolipoprotein binding

Cellular location

Secreted

General function & pharmacology

Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1, C4 and C5 .
PMID:6447255
Cleavage of fibronectin and laminin leads to cell detachment and apoptosis.

Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells

Sodium channel regulatory subunit beta-4

BE0004901

SCN4B

inhibitor

Specific functionsodium channel regulator activity

Cellular location

Cell membrane

General function & pharmacology

Regulatory subunit of multiple voltage-gated sodium (Nav) channels directly mediating the depolarization of excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na+ ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues. The accessory beta subunits participate in localization and functional modulation of the Nav channels .
PMID:24297919
Modulates the activity of SCN1A/Nav1.1 .
PMID:33712547
Modulates the activity of SCN2A/Nav1.2 PMID:24297919

Inward rectifier potassium channel 4

BE0009631

KCNJ4

inhibitor

Specific functioninward rectifier potassium channel activity

Cellular location

Cell membrane

General function & pharmacology

Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.

Can be blocked by extracellular barium and cesium

Voltage-dependent L-type calcium channel subunit beta-4

BE0009739

CACNB4

inhibitor

Specific functionprotein kinase binding

General function & pharmacology

The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

Alpha-1D adrenergic receptor

BE0004863

ADRA1D

antagonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Cell membrane

General function & pharmacology

This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

Transporters(4)

Proteins that transport this drug across cell membranes

Bile salt export pump

BE0000703

ABCB11

substrate

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Multidrug and toxin extrusion protein 1

BE0003657

SLC47A1

inhibitor

Specific functionantiporter activity

Cellular location

Cell membrane

General function & pharmacology

Multidrug efflux pump that functions as a H(+)/organic cation antiporter .
PMID:16330770 PMID:17509534
Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373

Mediates the efflux of endogenous compounds such as creatinine, vitamin B1/thiamine, agmatine and estrone-3-sulfate .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373

May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable)

Multidrug and toxin extrusion protein 2

BE0004752

SLC47A2

inhibitor

Specific functionantiporter activity

Cellular location

Cell membrane

General function & pharmacology

Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. Mediates the efflux of endogenous compounds such as, creatinine, thiamine and estrone-3-sulfate.

Plays a physiological role in the excretion of drugs, toxins and endogenous metabolites through the kidney

Carriers(1)

Proteins that carry this drug through the body

Alpha-1-acid glycoprotein 1

BE0000925

ORM1

binder

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

Scientific references(13)

Rayner-Hartley E., Sedlak T.

Ranolazine: A Contemporary Review.

Journal American Heart Assoc

2016 Mar 155(3):e003196. doi: 10.1161/JAHA.116.003196

PMID: 26979079 DOI: 10.1161/JAHA.116.003196

Saad M., Mahmoud A., Elgendy I.Y., Richard Conti C.

Ranolazine in Cardiac Arrhythmia.

Clinical Cardiology

2016 Mar39(3):170-8. doi: 10.1002/clc.22476. Epub 2015 Oct 13

PMID: 26459200 DOI: 10.1002/clc.22476

Reed M., Nicolas D.

ranolazine. doi: 10.

18578/bnf

895042288

PMID: 29939605 DOI: 10.18578/bnf.895042288

Mezincescu A., Karthikeyan V.J., Nadar S.K.

Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none? Sultan Qaboos Univ Med J. 2018 Feb;18(1):e13-e23. doi: 10.18295/squmj.2018.18.01.

003

Epub 2018 Apr 4

PMID: 29666676 DOI: 10.18295/squmj.2018.18.01.003

Codolosa J.N., Acharjee S., Figueredo V.M.

Update on ranolazine in the management of angina.

Vasc Health Risk Manag

2014 Jun 2410:353-62. doi: 10.2147/VHRM.S40477. eCollection 2014

PMID: 25028555 DOI: 10.2147/VHRM.S40477

Jerling M.

Clinical pharmacokinetics of ranolazine.

Clinical Pharmacokinetics

200645(5):469-91. doi: 10.2165/00003088-200645050-00003

PMID: 16640453 DOI: 10.2165/00003088-200645050-00003

Thomas D., Karle C.A., Kiehn J.

The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.

Curr Pharmacy Des

200612(18):2271-83. doi: 10.2174/138161206777585102

PMID: 16787254 DOI: 10.2174/138161206777585102

Balestrini S., Sisodiya S.M.

Pharmacogenomics in epilepsy.

Neurosci Lett

2018 Feb 22667:27-39. doi: 10.1016/j.neulet.2017.01.014. Epub 2017 Jan 10

PMID: 28082152 DOI: 10.1016/j.neulet.2017.01.014

Gomberg-Maitland M., Schilz R., Mediratta A., Addetia K., Coslet S., Thomeas V., Gillies H., Oudiz R.J.

Phase I safety study of ranolazine in pulmonary arterial hypertension.

Pulm Circ

2015 Dec5(4):691-700. doi: 10.1086/683813

PMID: 26697176 DOI: 10.1086/683813

Zweiker R., Aichinger J., Metzler B., Lang I., Wallner E., Delle-Karth G.

Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study.

Wien Klin Wochenschr

2019 Apr131(7-8):165-173. doi: 10.1007/s00508-019-1481-x. Epub 2019 Apr 8

PMID: 30963332 DOI: 10.1007/s00508-019-1481-x

Reddy B.M., Weintraub H.S., Schwartzbard A.Z.

The diastolic stress test: a new approach to an old problem.

Heart Failure Reviews

201116(4):339-349. doi: 10.1007/s10741-010-9217-z

PMID: 21224931 DOI: 10.1007/s10741-010-9217-z

Bhandari B., Subramanian L.

Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.

Recent Pat Cardiovasc Drug Discov

2007 Jan2(1):35-9. doi: 10.2174/157489007779606095

PMID: 18221101 DOI: 10.2174/157489007779606095

Chaitman B.R.

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.

Circulation

2006 May 23113(20):2462-72. doi: 10.1161/CIRCULATIONAHA.105.597500

PMID: 16717165 DOI: 10.1161/CIRCULATIONAHA.105.597500

ATC classification(1 code)

ATC C01EB18

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Ranolazine hydrochloride(DBSALT000388)

Experimental properties(5)

External resources(2)

RxList Drugs.com

Commercial products(101)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ranolazine

DB00243

CAS number

95635-55-5

UNII (FDA)

A6IEZ5M406

InChI Key (molecular fingerprint)

XKLMZUWKNUAPSZ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

23546

ChEBI

87690

PubChem Compound

56959

PubChem Substance

46505145

ChemSpider

51354

BindingDB

50173335

PharmGKB

PA164746007

Therapeutic Targets Database

DAP000875

Wikipedia

Ranolazine

ChEMBL

CHEMBL1404

RxCUI

35829

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9071

GenAtlas

PLG

GeneCards

PLG

GenBank Gene Database

X05199

GenBank Protein Database

387026

Guide to Pharmacology

2394

UniProtKB

P00747

UniProt Accession

PLMN_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10585

GenAtlas

SCN1A

GeneCards

SCN1A

GenBank Gene Database

AF225985

GenBank Protein Database

12642270

IUPHAR

578

Guide to Pharmacology

578

UniProtKB

P35498

UniProt Accession

SCN1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10582

GenAtlas

SCN10A

GeneCards

SCN10A

GenBank Gene Database

AF117907

GenBank Protein Database

4838145

IUPHAR

585

Guide to Pharmacology

585

UniProtKB

Q9Y5Y9

UniProt Accession

SCNAA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10583

GenAtlas

SCN11A

GeneCards

SCN11A

GenBank Gene Database

AF188679

GenBank Protein Database

6572950

IUPHAR

586

UniProtKB

Q9UI33

UniProt Accession

SCNBA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10588

GenAtlas

SCN2A

GeneCards

SCN2A

GenBank Gene Database

M94055

GenBank Protein Database

457879

IUPHAR

579

Guide to Pharmacology

579

UniProtKB

Q99250

UniProt Accession

SCN2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10590

GenAtlas

SCN3A

GeneCards

SCN3A

GenBank Gene Database

AJ251507

GenBank Protein Database

7414320

IUPHAR

580

Guide to Pharmacology

580

UniProtKB

Q9NY46

UniProt Accession

SCN3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10591

GenAtlas

SCN4A

GeneCards

SCN4A

GenBank Gene Database

M81758

GenBank Protein Database

338213

IUPHAR

581

Guide to Pharmacology

581

UniProtKB

P35499

UniProt Accession

SCN4A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10593

GenAtlas

SCN5A

GeneCards

SCN5A

GenBank Gene Database

M77235

GenBank Protein Database

184039

IUPHAR

582

Guide to Pharmacology

582

UniProtKB

Q14524

UniProt Accession

SCN5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10594

GeneCards

SCN7A

UniProtKB

Q01118

UniProt Accession

SCN7A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10596

GenAtlas

SCN8A

GeneCards

SCN8A

GenBank Gene Database

AF050736

GenBank Protein Database

4321647

IUPHAR

583

Guide to Pharmacology

583

UniProtKB

Q9UQD0

UniProt Accession

SCN8A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10597

GenAtlas

SCN9A

GeneCards

SCN9A

GenBank Gene Database

X82835

GenBank Protein Database

758110

IUPHAR

584

Guide to Pharmacology

584

UniProtKB

Q15858

UniProt Accession

SCN9A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10586

GeneCards

SCN1B

GenBank Gene Database

L10338

GenBank Protein Database

307415

UniProtKB

Q07699

UniProt Accession

SCN1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10589

GeneCards

SCN2B

GenBank Gene Database

AF007783

GenBank Protein Database

3309111

UniProtKB

O60939

UniProt Accession

SCN2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20665

GeneCards

SCN3B

GenBank Gene Database

AJ243396

GenBank Protein Database

7160975

UniProtKB

Q9NY72

UniProt Accession

SCN3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10592

GeneCards

SCN4B

GenBank Gene Database

AY149967

GenBank Protein Database

27465047

UniProtKB

Q8IWT1

UniProt Accession

SCN4B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6258

GenAtlas

KCNJ12

GeneCards

KCNJ12

GenBank Gene Database

L36069

GenBank Protein Database

567019

IUPHAR

431

Guide to Pharmacology

431

UniProtKB

Q14500

UniProt Accession

KCJ12_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6260

GeneCards

KCNJ14

Guide to Pharmacology

433

UniProtKB

Q9UNX9

UniProt Accession

KCJ14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6263

GeneCards

KCNJ2

UniProtKB

P63252

UniProt Accession

KCNJ2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6265

GeneCards

KCNJ4

Guide to Pharmacology

432

UniProtKB

P48050

UniProt Accession

KCNJ4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1393

GenAtlas

CACNA1F

GeneCards

CACNA1F

GenBank Gene Database

AJ006216

GenBank Protein Database

3183953

IUPHAR

531

Guide to Pharmacology

531

UniProtKB

O60840

UniProt Accession

CAC1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1403

GenAtlas

CACNB3

GeneCards

CACNB3

GenBank Gene Database

X76555

GenBank Protein Database

435135

UniProtKB

P54284

UniProt Accession

CACB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1404

GenAtlas

CACNB4

GeneCards

CACNB4

GenBank Gene Database

U95020

GenBank Protein Database

2058727

UniProtKB

O00305

UniProt Accession

CACB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:25588

GeneCards

SLC47A1

GenBank Gene Database

AK001709

GenBank Protein Database

7023138

Guide to Pharmacology

1216

UniProtKB

Q96FL8

UniProt Accession

S47A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:26439

GeneCards

SLC47A2

Guide to Pharmacology

1217

UniProtKB

Q86VL8

UniProt Accession

S47A2_HUMAN

International reference pricing

4 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $4.04/tablet

To $6.89/tablet

Ranexa 500 mg tablet

$4.04/tablet

Ranexa 500 mg 12 Hour tablet

$4.06/tablet

Ranexa 1000 mg tablet

$6.63/tablet

Ranexa 1000 mg 12 Hour tablet

$6.89/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

3 active patents, 10 expired

10898444

United States

Approved 26 Jan 2021 · Expires 24 Jan 2038

11y 9m

11510878

United States

Approved 29 Nov 2022 · Expires 24 Jan 2038

11y 9m

12161761

United States

Approved 10 Dec 2024 · Expires 24 Jan 2038

11y 9m

6303607

United States

Approved 16 Oct 2001 · Expires 27 May 2019

Expired

6479496

United States

Approved 12 Nov 2002 · Expires 27 May 2019

Expired

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Ranolazine 375mg modified-release tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
13

Chemical identifiers

Ranolazine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Ranolazine 375mg modified-release tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science13

Chemical identifiers

Ranolazine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
13